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Based on the Food and Drug Administration’s Modiﬁed Risk Tobacco Product (MRTP) Application draft
guideline, Philip Morris International (PMI) has developed a Population Health Impact Model to estimate
the reduction in the number of deaths over a period following the introduction of an MRTP. Such a model
is necessary to assess the effect that its introduction would have on population health, given the lack of
epidemiological data available prior to marketing authorization on any risks from MRTPs. The model is
based on publicly available data on smoking prevalence and on the relationships between smoking-re-
lated disease-speciﬁc mortality and various aspects of the smoking of conventional cigarettes (CCs),
together with an estimate of exposure from the MRTP relative to that from CCs, and allows the explo-
ration of possible scenarios regarding the effect of MRTP introduction on the prevalence of CC and
MRTP use, individually and in combination. By comparing mortality attributable in a scenario where
the MRTP is introduced with one where it is not, the model can estimate the mortality attributable to
CCs and the MRTP, as well as the reduction in the deaths attributable to the introduction of the MRTP.
 2015 The Authors. Published by Elsevier Inc. This is an open access article under theCCBY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
To obtain a risk modiﬁcation order under the United States
Food and Drug Administration’s draft guidance (FDA, 2012), the
applicant must demonstrate that the Modiﬁed Risk Tobacco
Product (MRTP) beneﬁts the health of the population as a whole,
accounting for current, former and never smokers. Given the lack
of population-level data available prior to marketing an MRTP on
its risks or the level of uptake, Philip Morris International (PMI) is,
in accordance with Section VI.B.4 of the draft guidance, develop-
ing a Population Health Impact Model to estimate the impact of
the introduction of the product on mortality given assumptions
concerning the exposure to the smoker from the MRTP relative
to that from conventional cigarettes (CCs), and on the rate ofuptake of the MRTP. The model estimates the impact on mortality
in a population which survives until a speciﬁc time after the
introduction of the MRTP on the market. Although the model
was developed with focus on the US, it is also intended to be used
for population health impact assessment in other countries, such
as the UK, Germany, and Japan, for which the required data are
available.
To predict the potential impact from the introduction of an
MRTP, the model will allow the exploration of a wide range of
scenarios assessing the possible effect of MRTP introduction on
the prevalence of CC and MRTP use, individually and in com-
bination. The input data are extracted from publicly available
databases and the scientiﬁc literature, and are country-speciﬁc
where available and applicable. The attributable deaths under
the ‘‘MRTP Scenario’’ (with the introduction of the MRTP) will
be compared with those under the ‘‘Null Scenario’’ (without the
introduction of the MRTP) to estimate the reduction in attributa-
ble deaths. The purpose of this article is to describe, in detail, the
data sources, modeling methodology, rationale and approach to
the assessment of the potential impact from the introduction of
an MRTP.
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2.1. Prevalence (P)-component
The P-component is a Markov chain state-transition model to
estimate changes in the distribution of CC and/or MRTP use occur-
ring in a hypothetical population of a given size over a deﬁned per-
iod, separately for the Null and MRTP Scenarios. Before the MRTP is
introduced, the population has a country-speciﬁc distribution of CC
smoking habits (current, former [by years since quitting] and never
smoking). The population is followed over the simulation period by
considering successive small time intervals, typically one year,
during which only one change in smoking habits can occur.
Smoking transition probabilities (STPs) are applied to each mem-
ber of the population to determine whether they stay in the same
group or change to a different one by the end of each interval. The
STPs can vary based on the time since introduction of the MRTP
and/or the time that the population member has spent in their cur-
rent state. Thus, by the end of the simulation period, each member
will have a complete smoking history, updated age, and (for former
smokers) updated time since quitting.
Under the Null Scenario, the smoking histories relate only to use
or non-use of CCs. Thus the possible STPs relate to never smokers
starting to smoke CCs, current CC smokers quitting CCs, and former
CC smokers reinitiating CCs. Under the MRTP Scenario, both CCs
and the MRTP are available, increasing the complexity of the
STPs. The possible STPs relate to never smokers starting to use
the MRTP or CCs, former smokers re-initiating with the use of
the MRTP or CCs, and current users of the MRTP or CCs quitting
use of the product, or switching to the other product.
2.1.1. Data and data sources
The P-component will be populated with the distribution of CC
smoking for twelve countries (Austria, Canada, France, Germany,
Hungary, Italy, Japan, Poland, Sweden, Switzerland, the United
Kingdom and the United States from 1986 onwards), but is
expandable to allow the inclusion of additional data from future
years and/or additional countries and regions.
2.1.1.1. Current and former smoking prevalence data. Prevalence
data on current CC smoking will be extracted from International
Smoking Statistics (ISS; Forey et al., 2002; Forey and Lee, 2002).
Smoking prevalence data speciﬁc for sex-, age (in 5-year groups)
and period (in 5-year groups) are available from all twelve coun-
tries up to at least 2005 (Forey et al., 2006–2013; Forey et al.,
2007).
Age- and sex-speciﬁc prevalence data on former CC smokers,
extracted from the same sources used for the ISS database, are
readily available (Lee et al., 2009) for Austria, Canada, Germany,
the United Kingdom and the United States. Data for Italy and
Japan have been extracted, but are not yet published. Data extrac-
tion is planned for France, Hungary, Poland, Sweden and
Switzerland, to ensure that there is prevalence data on former
smokers from the same countries as the data on current CC
smokers.
2.1.1.2. Distribution of former smokers by years quit. National age-
and sex-speciﬁc data on the distribution of former smokers (by
years since quitting) are also required. Preliminary investigations
found data for all the countries, except Poland, but the publications
vary in scope and quality, some using broad grouping of years since
quitting, some presenting results only for limited age groups, and
some being based on small samples. Further attempts will be made
to obtain data by concentrating on data sources allowing cus-
tomized analysis. Where relevant data cannot be found for a givencountry, the distribution may be estimated using the data for other
countries that are similar with respect to economic and cultural
aspects, including tobacco use history.
2.1.1.3. Estimating STPs for CCs from smoking distributions. Data on
the prevalence of current and former CC smoking within the same
birth cohort in successive periods do not allow direct estimation of
STPs. This can be seen when examining the changes in the propor-
tion of former CC smokers between periods. An increase from 36%
in period 1 to 39% in period 2 could reﬂect 3% of the current CC
smokers quitting smoking during the period, but cannot be distin-
guished from a scenario where 6% of former smokers re-initiated
CC smoking, while 9% of CC smokers quit. Therefore, national data
on the re-initiation rates of former smokers are required to esti-
mate the STPs more precisely.
2.1.1.4. Estimating STPs for the MRTP. In the pre-market setting, STP
estimates for the MRTP Scenario will be based on assumptions and
product use patterns from controlled studies that cannot be vali-
dated with regard to post-market actual use. After the introduction
of the MRTP, the preliminary STP estimates can be replaced by
estimates derived using the data from a series of longitudinal
cross-sectional surveys that are planned to initiate at the time of
product launch. These cross-sectional surveys will also provide
data on re-initiation rates for CCs.
2.1.2. Smoking histories
The smoking histories will be modeled starting with a large
hypothetical population sample (e.g., 10,000). The start year is
assumed to be before the introduction of the MRTP, so the
population will be initially subdivided according to the sex-, age-
and country-speciﬁc distribution of CC smoking status (current,
former [by time since quitting], never) for that year. The pop-
ulation will then be followed up at successive small time intervals
(typically one year) over a deﬁned period. During any interval, the
smoking status of each population member may change, assuming
that smoking status can only change once per interval because the
length of the time interval is sufﬁciently short to ignore multiple
changes. The probabilities of these transitions are deﬁned by the
STPs. Although it is expected that the STPs will remain constant
from year to year, the model will allow the STPs to vary over the
period. At the end of the period, each population member will have
a history of tobacco use. These histories will then be used to deter-
mine the distributions of CC and MRTP use at any time following
the introduction of the MRTP and so allow the estimation of dis-
ease risks.
Where the end of the period is a recent year, the STP values for
the Null Scenario can be selected based on time trends in smoking
habits obtained from the data on current and former CC smoker
prevalence. The smoking distribution predicted by the P-compo-
nent at the end of the follow-up period should be closely aligned
with its known distribution. The effects of alternative assumptions
concerning the trends in smoking distributions and the choice of
STPs will be considered in sensitivity analyses.
Fig. 1 shows the matrix of STPs required for the Null Scenario.
Determining how smoking habits change in an interval requires
knowledge of three STPs, PNC = the probability that a never smoker
(N) becomes a current smoker (C), PCF = the probability that a cur-
rent smoker (C) becomes a former smoker (F), and PFC = the proba-
bility that a former smoker (F) becomes a current smoker (C).
The diagonal of the matrix running from the top left to bottom
right reﬂects a situation without change in smoking habits. The
cells marked with a zero are excluded because for two of these
(a current or former smoker becoming a never smoker) the transi-
tion is impossible, while for the other (a never smoker becoming a
former smoker) the transition requires multiple changes which
Fig. 1. STP matrix if the MRTP is not introduced (Null Scenario). N = never smoker;
C = current smoker; F = former smoker; PNC = probability a never smoker starts
smoking; PFC = probability a former smoker re-initiates smoking; PCF = probability a
current smoker quits smoking.
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older than 35 years.
Fig. 2 shows the matrix of STPs required for the MRTP Scenario.
Here determining how smoking habits change within an interval
requires knowledge of eight STPs. During each interval a
population member can either remain in their current state or
transition to the two other potential states. Again transitions to a
never smoker or from a never to a former smoker are excluded.
It is important to account for interdependencies between the
STPs. A transition to current MRTP use may be associated with
quitting CC smoking, while reinitiating CC smoking by former
smokers may be associated with quitting MRTP. Further, the set
of STPs may vary by the time a population member has spent in
each state and for the past states that they have been in (e.g., a
smoker who has previously quit may be more likely to quit, and
short-term quitters may be more likely than long-term quitters
to re-initiate).
In the ﬁrst place, it will be assumed that the probability of
re-initiating smoking is independent of the product previously
used. If post-marketing data reveals such a dependency, allowance
can be made for this. The STP matrix also accounts for the proba-
bility that a never smoker initiates smoking. For older individualsFig. 2. STP matrix if the MRTP is introduced (MRTP Scenario). N = never smoker;
CC = current smoker of CCs; CM = current user of MRTP; F = former smoker;
PNC = probability a never smoker starts smoking CCs; PFC = probability a former
smoker re-initiates smoking CCs; PCF = probability a current smoker of CCs quits
smoking; PMC = probability a current MRTP user switches to smoking CCs;
PNM = probability a never smoker starts using MRTP; PCM = probability a current
smoker of CCs switches to using MRTP; PFM = probability a former smoker starts
using MRTP; PMF = probability a current user of MRTP quits using MRTP. The
probabilities in each column add up to unity.(above 35 years), this is likely to be zero. Although this is probably
also the case for the MRTP, it may not necessarily be true.
Using the STP matrices presented in Figs. 1 and 2, the P-compo-
nent generates distributions of smoking histories for each scenario
at the end of the period being studied. These are then used in the
E-component to estimate the reduction of smoking-attributable
deaths in a population who survived since the introduction of
the MRTP.
2.1.3. Considerations related to the P-component
2.1.3.1. Length of follow-up. The P-component will allow for follow-
up of a population over up to 20 years. While the methodology
could be extended to longer periods, such long-term projections
may be unreliable.
2.1.3.2. Age range. As the epidemiologic risk (E)-component (see
Section 2.2) requires data for the age range 30–79 years after up
to 20 years follow-up, the initial age required in the population
to be followed is 10 years. The E-component therefore starts with
a population aged 10–79 years, and follow-up continues until they
reach 79 years of age or the end of the follow-up period. This
enables calculations of distributions of smoking habits for ages
ranging from 30–79 years for the entire follow-up period.
2.1.3.3. Amount smoked. The P-component does not account for
amount smoked and the STPs do not account for the possibility
that a person continues to smoke the same product but changes
the amount that they smoked.
2.1.3.4. Products other than CCs and MRTP. The P-component does
not consider other tobacco products, such as cigars, pipes, or
smokeless tobacco, which may bias the estimation of the reduction
of deaths attributable to an MRTP if CC smokers switching to the
MRTP tend to change their use of these other products. Unless evi-
dence emerges that this occurs to any material extent, this
possibility will not be accounted for because the estimation pro-
cess would be overly complex.
2.2. Epidemiologic risk (E)-component
The E-component uses the smoking histories produced by the
P-component to estimate the smoking-related attributable deaths
from lung cancer (LC), ischemic heart disease (IHD), stroke, and
chronic obstructive pulmonary disease (COPD). The difference
between the number of deaths estimated under the Null Scenario
and that estimated under the MRTP Scenario is an estimate of
the change in the number of deaths from smoking-related diseases
associated with the introduction of the MRTP. The model will only
consider deaths between the ages of 30–79 years because there are
extremely few smoking-related deaths before the age of 30 years,
diagnoses at ages above 80 years are unreliable, and mortality
and population data for some countries and years are unavailable
for age groups above 75–79 years. As deaths will be estimated by
age group, the model can also be used to estimate premature mor-
tality (death before age 75).
For each sex and age group, the number of smoking-attributable
deaths are estimated using relative risk (RR) estimates, for current
and former smokers relative to never smokers. The RR estimates
for current CC smokers are country-, disease-, sex- and age-speciﬁc
and are based on meta-analyses of epidemiological data. For for-
mer CC smokers, the RR estimates by time since quitting are
derived from the corresponding estimates for current smokers,
assuming that the decrease in excess risk (ER = RR  1) after quit-
ting follows a negative exponential function. Disease-speciﬁc esti-
mates of the half-life of the decrease are obtained by ﬁtting the
function to published data sets. As detailed elsewhere (P.N. Lee
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negative exponential model (NEM) align closely with those of the
multistage model, known to predict various observed features of
the relationship between smoking and lung cancer (Lee, 1995).
If the ‘‘effective dose’’ is taken as 1 unit when smoking CCs, and
as 0 units when not smoking, then the effective dose when using
the MRTP is taken as F units (assumed to be <1). The smaller is F,
the smaller the ER associated with use of the MRTP, and the closer
the ER associated with switching from CCs to the MRTP becomes to
zero, the ER associated with smoking cessation. Using the F value,
the disease-speciﬁc RR estimates for current CC smokers, and the
disease-speciﬁc half-life estimates associated with smoking cessa-
tion, the ERs associated with switching from CC to MRTP use can be
derived.
Direct quantiﬁcation of Fwould require long-term large-sample
epidemiological health-outcome studies which cannot be con-
ducted for a novel MRPT not yet marketed. Available indirect
empirical CC vs. MRTP comparative evidence includes: (a) aerosol
chemistry data on harmful and potentially harmful smoke con-
stituents, (b) standard toxicology assessments (including cytotoxi-
city and mutagenicity assays) comprising in vitro and in vivo
rodent inhalation study results, (c) pharmacokinetic and smoking
topography data obtained from single and ad libitum product use
clinical conﬁnement and ambulatory studies, (d) analysis of blood
and urinary biomarkers of exposure measured in clinical studies on
smokers switching from CC to MRTP or smoking abstinence, and
(e) measurements of functional and subjective health as well as
clinical risk endpoints obtained from extended ambulatory cessa-
tion studies and long-term exposure response studies. Methods
of aggregating these data are being developed to estimate the
likely probability density of F considering the integrated available
empirical evidence. Since there is inevitably uncertainty in the esti-
mate, the population health impact will also be assessed using
alternative plausible estimates of F.
2.2.1. Data and data sources
2.2.1.1. National population size and mortality data. Country-, sex-
and age-speciﬁc data for recent years on the number of deaths
from LC, IHD, stroke, and COPD for twelve countries of interest will
be extracted from the latest World Health Organization estimates.
Population size estimates, available for these countries from 1950
to 2010 (United Nations Population Division, 2010), will be used to
convert numbers of deaths to death rates.
2.2.1.2. Relative risks. PMI has compiled databases containing the
published epidemiological evidence of CC smoking-related risks
of LC, IHD, stroke, and COPD. The lung cancer database includes
287 epidemiological studies published prior to 2000, each with
over 100 cases of LC (Fry et al., 2013a; Lee et al., 2012a). The
COPD database includes 133 studies published prior to 2007
(Forey et al., 2011). The database for IHD and stroke is more lim-
ited, including 43 studies published since 1990. These databases,
recently expanded to include published studies related to smok-
ing cessation, will be used to derive RR estimates of current
and former smokers relative to never smokers by sex, period,
and region. The evidence available from these databases suggests
that the ER for current smoking varies linearly with amount
smoked; thus, derivation of consumption-speciﬁc RRs is not
needed.
2.2.2. Methodology
2.2.2.1. Half-life of excess risk. Recent research has shown that the
decline of ER by time since quitting CC smoking is well described
using a negative exponential model, with the ﬁt of the model being
shown to be adequate for IHD, stroke, and COPD (Lee et al., 2012b,
2014a,b), and for LC, provided that correction is made for reversecausation (Fry et al., 2013b). The decline in the ER is described
by the half-life parameter (the time at which half the ER associated
with continued CC smoking has disappeared), and varies signiﬁ-
cantly by disease, from about 5 years for IHD and stroke, to about
10 years for LC, and 13 years for COPD.
2.2.2.2. Negative exponential model. The negative exponential
model used to describe the decline in disease-speciﬁc ER following
smoking cessation is given in Eq. (1):
ERQ ða; tÞ ¼ ERCðaÞ exp tL=Hf g ð1Þ
where a is age, t is the time since quitting, ERQ(a) is the excess risk
for quitters, ERC(a) is the ER for current CC smokers, L is loge2, and H
is the disease-speciﬁc half-life.
Eq. (1) describes the change in ER following a change in the
effective dose from 1 to 0 units. The model can be adapted to
describe the change in ER following a change in effective dose from
1 to F units, given in Eq. (2):
ERCHða; tÞ ¼ ERCðaÞ½F þ ð1 FÞ exp tL=Hf g ð2Þ
Here t is the time since the transition to the MRTP, and ERCH(a)
is the ER following the change.
In practice, the patterns of CC and MRTP use may become more
complex (e.g., current CC smokers may switch to MRTP and then
restart smoking CCs, or former smokers may take up MRTP). A fur-
ther adaptation of the negative exponential model is designed to
cater for such situations. Deﬁning ER1(a) as the ER relating to the
habit being switched from, ER2(a) as that relating to the habit being
switched to, the estimated ER relating to the switcher, ERSW(a,t), is
then derived from
ERSWða; tÞ  ER2ðaÞ½ = ER1ðaÞ  ER2ðaÞ½  ¼ exp tL=Hf g ð3Þ
In Eq. (3), t is the time since the switch in habits. Note that Eq.
(3) is consistent with Eqs. (1) and (2). Thus, with some rearrange-
ment, substituting ER2(a) = 0 and ER1(a) = ERC(a) gives Eq. (1),
while substituting ER2(a) = FERC(a) and ER1(a) = ERC(a) gives Eq.
(2). Eq. (3) can be used repeatedly for an individual following a
sequence of changes, in order to estimate the ER at the end of
the follow-up period, as described in more detail elsewhere (P.N.
Lee et al., personal communication).
2.2.2.3. Number of deaths and increase in death rates associated with
smoking. For each of the causes of death considered, death rates
and numbers of smoking-attributable deaths will be estimated
separately for the Null Scenario and the MRTP Scenario. For the
Null Scenario, for a given country, year, sex, age group, and cause
of death, data are assumed to be available for population size (N)
and total number of deaths (D). The P-component outputs Null
Scenario-speciﬁc estimates of use prevalence (Pi) by mutually
exclusive CC smoking groups (i = 0, 1, . . ., s), where i = 0 corre-
sponds to never smoking, and s is the number of ever smoking
groups in this scenario. The smoking groups not only include cur-
rent smokers and quitters that have quit for various periods of
time, but also those who have quit and re-initiated, possibly multi-
ple times.
The corresponding estimates RRi are derived with RR0 deﬁned as
1, as described above. If A0 is the death rate of never smokers, then
the number of deaths can be calculated as
D ¼ NA0
Xs
i¼0
PiRRi ð4Þ
and the death rate in never smokers can be estimated by
A0 ¼ D= N
Xs
i¼0
PiRRi
 !
ð5Þ
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Ai ¼ A0RRi ð6Þ
The number of deaths in never smokers is given by
D0 ¼ NA0P0 ð7Þ
and the number of deaths that would have occurred if everyone had
the same death rate as never smokers is given by
D ¼ NA0 ð8Þ
The number of smoking-attributable deaths, DATTRIB, is given by
the following:
DATTRIB ¼ D D ð9Þ
The increase in the rate attributable to smoking, AATTRIB, is given
by the following:
AATTRIB ¼ D=N  A0 ð10Þ
The MRTP Scenario uses the same estimates of population size
(N) and total mortality (D) as before. However, the output from
the P-component is from the distribution assuming that an MRTP
was introduced, which provides estimates of prevalence (P0j) by
mutually exclusive groups of CC and/or MRTP usage (j = 0, 1, . . .,
s0), where j = 0 corresponds to never users of either product, and
s0 is the number of ever user groups in this scenario. The
corresponding estimates RR0j are again derived as described above.
It is assumed that the death rate in the never user group, A00, is the
same as that for never smokers, A0, so that mortality rates in the
other groups, A0j, are given by
A0j ¼ A0RR0j ð11Þ
Assuming that the population size N is unaltered, the total
number of disease-speciﬁc deaths can then be calculated as
D0 ¼ N
Xs0
j¼0
PjA
0
j
 
ð12Þ
The reduction in the number of smoking-attributable deaths
following the introduction of MRTP, DLESS, is then given by
DLESS ¼ D D0 ð13Þ
The reduction in the death rate following the introduction of
MRTP, ALESS, is given by the following:
ALESS ¼ DLESS=N ð14Þ
The summation of DLESS over the sexes, ages, and causes of death
is considered to estimate the overall effect of the introduction of
the MRTP on the population that survives until the time point of
interest.
The effect of the introduction of the MRTP can also be estimated
for both sexes separately and for speciﬁc age groups. Estimates of
the effect on premature mortality (deaths before 75 years of age)
can be derived from the data by age.
These calculations are based on the assumption that the pop-
ulation size is the same under both scenarios. However, given that
the introduction of the MRTPmay decrease the death rate, the pop-
ulation size would be expected to be larger under the MRTP
Scenario. Thus, if N⁄ is the increased population size for the
MRTP Scenario, Eqs. (12) and (13) would be revised as follows:
D00 ¼ D0N=N ð15Þ
D00LESS ¼ D D00 ð16Þ
The increase in population size associated with the introduction
of the MRTP can be estimated from the all-cause annual survival
rates of the population for the year studied for both scenarios.Suppose that where the P-component concerns the possible intro-
duction of the MRTP 20 years ago, the population size at the end of
the 20 year period is N, the total number of deaths from LC, IHD,
stroke, and COPD is d1 under the Null Scenario and d2 under the
MRTP Scenario, and the total number of deaths from all other
causes is d3. The relative survival rate for the MRTP Scenario com-
pared with the Null Scenario, u, can then be estimated by
u ¼ ðN  d2 d3Þ=ðN  d1 d3Þ ð17Þ
Given that, after 20 years, the relative annual survival rate
associated with the introduction of the MRTP is u, and assuming
that the logarithm of the relative annual survival rate increases lin-
early with years elapsed since the introduction of theMRTP (a plau-
sible ﬁrst approximation assuming that the STPs vary little over
time), the relative annual survival rate after n years can be approxi-
mated by un/20. Thus, the survival rate over the entire 20-year per-
iod for the MRTP Scenario, relative to that for the Null Scenario, can
be approximated by multiplying the 20 terms u1/20, u2/20, . . ., u20/20,
resulting in u10.5. This yields an estimate of the ratio required in Eq.
(15), N⁄/N. Even if the STPs change with time, this approach may
yield a reasonable approximation to N⁄/N. In theory, a more precise
approach might be derived by dividing the follow-up period into
intervals, with time invariant STPs, and estimating the effects on
population size at the end of each interval.
2.2.2.4. Sensitivity analyses. Total and smoking-attributable deaths
under the Null and MRTP Scenarios and their difference (reduction
associated with introduction of MRTP) will be estimated in total,
and separately by disease, sex, age, and smoking groups.
Separating results for ever CC smokers who never used MRTP
and MRTP users who never smoked CC should allow better under-
standing of the effects of the MRTP introduction on a speciﬁc pop-
ulation surviving since the MRTP launch. Not only can these results
be obtained assuming that the population size is the same under
both scenarios, based on Eqs. (4)–(14), but revised estimates can
also be obtained accounting for the larger population assumed
under the MRTP Scenario.
The method described above results in smoking history dis-
tributions that are based on single samples generated in the P-
component under the Null and MRTP Scenarios based on the given
STPs. This may result in uncertainty, and this can be assessed by
comparing the results from multiple samples. Samples can also
be generated using multiple sets of STPs to allow sensitivity analy-
ses on how the estimates of smoking-attributable deaths depend
on the choice of STPs. Similarly, as noted above, sensitivity analy-
ses can also investigate the dependence of the estimates of smok-
ing-attributable deaths on the F value chosen. Another source of
error is the reliance on the RR and half-life estimates derived from
meta-analyses. As these also provide variability estimates, based
on random-effects models, sensitivity analyses can also be con-
ducted (e.g., using alternative estimates ±1 standard error of the
mean).3. Discussion
We have described above the methods proposed for the estima-
tion of the effect of MRTP introduction on LC, COPD, IHD, and
stroke mortality. The methods account for many aspects of the
smoking habit, including prevalence of current and former smok-
ing, level of exposure, and time since quitting or switching.
However, the duration of smoking at the start of the period is
not considered in this analysis because the age-speciﬁc RRs used
for CC smoking in the E-component reﬂect duration of smoking
to a considerable extent, with minor variations in age of starting
to smoke. Furthermore, it would be difﬁcult to obtain valid sex-
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to smoke for the countries of interest. Failure to consider duration
of smoking might lead to error in estimating the reduction in mor-
tality associated with switching to an MRTP if, for example, those
switching from CCs to the MRTP tended to be smokers with a
below- or above-average duration of smoking. If this is the case,
the P-component may have to be amended. Until this can be con-
ﬁrmed, we have omitted such an allowance to avoid added
complexity.
If smokers switching from CCs to MRTP do not change their con-
sumption per day, and if the risk of a disease is linearly related to
the amount smoked, it seems reasonable to estimate the ‘‘effective
dose’’, F, from data on exposure to cigarettes and relevant smoke
constituents for MRTP smokers, relative to CC smokers. The F value
can be adjusted to account for the failures of these assumptions.
Thus, if there are changes in consumption on switching, F might
be estimated based on relative daily exposure, rather than on rela-
tive exposure estimated on a per-cigarette basis. Similarly, non-lin-
earity in the dose–response relationship may also be considered.
This may be relevant if, for some diseases, the evidence suggests
that the ER decreases less than proportionately to the amount
smoked. Inevitably, there will be uncertainty in the estimation of
F, given the lack of precise data on the response relationships with
amount smoked owing to the incomplete knowledge of the
association of relevant smoke constituents for each of the diseases
considered, and because the risk from repeated exposure to small
doses may not be estimated reliably from less frequent exposures
to higher doses. In this model, this uncertainty will be addressed by
sensitivity analyses with varying values of F.
Regarding the estimation of the mortality reduction associated
with the introduction of an MRTP, environmental tobacco smoke
exposure (ETS) is not considered. Recently updated meta-analyses
of the epidemiological evidence on ETS and LC (Lee et al., 2013c,e),
COPD (Lee et al., 2013a), IHD (Lee et al., 2013b,d), and stroke (Lee
et al., 2013f) have shown that the RRs associated with ETS expo-
sure in never smokers are much lower than the corresponding
RRs for current smoking. Thus, for example, for LC, the RR for ETS
exposure is currently estimated at 1.26, while that for current
smoking is estimated at 8.43 (Lee et al., 2012a), the ER for ETS
exposure being 0.26/7.43 = 3.5% of that for current smoking. This
calculation suggests that whether or not the MRTP reduces the risk
from ETS exposure would have little effect on the estimates of the
reduction of mortality associated with MRTP introduction.
The proposed methods do not account for risk factors other
than smoking that may affect the four diseases studied. This seems
reasonable given that the introduction of an MRTP is not expected
to affect their distribution. If evidence emerges that using or
switching to MRTP substantially affects other factors unexpectedly
(e.g., degree of alcohol consumption), then the methods proposed
may require modiﬁcation.
Although the P-component involves stochastic simulation to
generate samples of smoking history distribution, the E-compo-
nent does not involve simulation. The estimation of mortality rates
involves age-, sex-, and country-speciﬁc data on cause-speciﬁc
mortality and population size for the year of interest. Then, the
smoking histories and RRs are applied to estimate the mortality
rates attributable to smoking, without any allowance for variation
in the number of subjects with a given tobacco history.
Although aging of the population and its effect on the STPs is
accounted for by the P-component, it does not consider the mortal-
ity of the population during the period of interest; thus, the sim-
ulation is performed considering the survival of the entire
population. For younger age groups, where the great majority
survives the follow-up period, the differential mortality of never
smokers, quitters, and current smokers is irrelevant. For olderage groups, the STPs may result in some underestimation of never
smokers and overestimation of ever smokers. Therefore, while in
the absence of mortality, the proportion of never smokers in a
cohort cannot increase with increasing age, because transition into
a never smoker is not possible, the proportion can rise in a true
population because of the better survival of never than ever smo-
kers. The resulting bias should, however, effect similarly the smok-
ing habit distributions derived for both the Null and MRTP
Scenarios. In addition, the E-component is adjusted for differing
survivals under the two scenarios.
The E-component may estimate MRTP-related reductions in
deaths from some diseases even when rates actually rise. This is
not indicative of an error; it is merely reﬂecting underlying adverse
trends in risk factors other than cigarettes (e.g., obesity). In this sit-
uation, the estimate would suggest that had the MRTP not been
introduced, the rise in rates from these diseases would have been
greater.
The analysis is restricted to the most common smoking-related
diseases as it would be difﬁcult to obtain reliable estimates of the
RR and half-life for all the less common diseases associated with
smoking. Estimates for industrialized countries reported by
Ezzati and Lopez (2003) in 2000 showed that there were a total
of 2,427,000 smoking-attributable deaths (1,815,000 in men and
612,000 in women) and, of these, 1,853,000 (1,361,000 in men
and 492,000 in women) were from LC, COPD, or cardiovascular dis-
eases. Given that (Peto et al., 1994) IHD and stroke deaths corre-
spond to 75% of the total 1,022,000 deaths from cardiovascular
diseases (753,000 in men and 269,000 in women), and assuming
that the relative risk from smoking is similar for all vascular dis-
eases (Peto et al., 1994), the number of smoking-attributable
deaths would reduce to 1,598,000 (1,173,000 in men and 425,000
in women). This corresponds to 66% (65% in men and 69% in
women) of the total. Assuming that the proportional reduction of
risk from introducing an MRTP is similar for all smoking-related
diseases, this implies that overall estimates of deaths saved by a
MRTP based on the four diseases studied would have to be multi-
plied by approximately 1.52 (1.55 in men, 1.44 in women) to yield
an estimate for all smoking-related diseases.
4. Conclusion
The Population Health Impact Model estimates the reduction in
the number of deaths attributable to smoking associated with the
introduction of an MRTP by comparing, for a given year, the smok-
ing-attributable mortality estimated to occur were the MRTP intro-
duced a deﬁned number of years before, with that estimated to
occur were it not introduced. The difference should be indicative
of the population-level effect of an MRTP introduction. The esti-
mates may relate to a year in the future, where effects of current
introduction of an MRTP are of interest, or to a recent year, where
the hypothetical effects of a past MRTP introduction are being
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